文献速递肝病消化道肿瘤与早癌

高加索慢性乙型肝炎患者长期恩替卡韦或替诺福韦治疗肝细胞癌风险相似

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
PubMed 文献 · J Hepatol · 2020-06-16

在PAGE-B多中心队列的1935例高加索慢性乙型肝炎患者中,比较恩替卡韦(ETV,n=772)与替诺福韦二吡呋酯(TDF,n=1163)单药治疗的肝细胞癌(HCC)发生率。平均随访7.1±3.0年,5年累积HCC发生率ETV组5.4% vs TDF组6.0%(log-rank,p=0.321),无显著差异;第5年肝硬化弹性成像逆转(肝硬度<12 kPa)TDF组73.8% vs ETV组61.5%(p=0.038)。

要点

  • ETV与TDF单药治疗的5年累积HCC发生率无显著差异(5.4% vs 6.0%,p=0.321)。
  • 治疗期间生化/病毒学缓解、HBsAg清除、肝移植或死亡在两组间相似。
  • 治疗前肝硬化患者第5年肝硬化弹性成像逆转TDF组较ETV组更常见(73.8% vs 61.5%,p=0.038)。

核心结论

  • 在高加索慢性乙型肝炎患者中,无论是否伴有肝硬化,长期ETV或TDF单药治疗的HCC风险、生化/病毒学缓解率、HBsAg清除率及肝移植或死亡率相似,但第5年肝硬化弹性成像逆转在TDF组更常见。

研究设计与样本

  • 欧洲PAGE-B多中心队列中纳入1935例高加索慢性乙型肝炎患者,伴或不伴代偿性肝硬化,接受ETV单药治疗(n=772)或TDF单药治疗(n=1163),自ETV/TDF起始平均随访7.1±3.0年。

主要发现

  • 5年累积HCC发生率ETV组为5.4%,TDF组为6.0%(log-rank,p=0.321),在任何患者亚组(伴或不伴肝硬化、初治或经口服抗病毒药物经治)中均无显著差异。
  • 多变量Cox回归分析中,调整多个HCC危险因素后,ETV与TDF治疗患者的HCC风险相似。
  • ETV与TDF治疗患者的治疗期间生化缓解和病毒学缓解率、HBsAg清除率、肝移植和/或死亡率相似。
  • 治疗前肝硬化患者第5年肝硬化弹性成像逆转(肝硬度<12 kPa)见于245/347例(70.6%),TDF组较ETV组更常见(73.8% vs 61.5%,p=0.038)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than entecavir (ETV), but this finding remains controversial. We aimed to identify any differences in HCC incidence, or other patient outcomes, between patients receiving TDF or ETV in the well monitored, multicenter European PAGE-B cohort. METHODS: We included 1,935 Caucasians with CHB, with or without compensated cirrhosis, treated with ETV (n = 772) or TDF (n = 1,163) monotherapy. Mean follow-up was 7.1 ± 3.0 years from ETV/TDF onset. RESULTS: The 5-year cumulative HCC incidence was 5.4% in ETV- and 6.0% in TDF-treated patients (log-rank, p = 0.321), with no significant difference in any patient subgroup (with or without cirrhosis, naïve or experienced to oral antiviral(s) [total, with or without cirrhosis]). In multivariable Cox regression analyses, the hazard of HCC was similar between ETV- and TDF-treated patients after adjustment for several HCC risk factors. ETV- and TDF-treated patients had similar rates of on-therapy biochemical and virological remission, HBsAg loss, liver transplantation and/or death. Elastographic reversion of cirrhosis at year 5 (liver stiffness <12 kPa) was observed in 245/347 (70.6%) patients with pretreatment cirrhosis, being more frequent in TDF- than ETV- treated patients (73.8% vs. 61.5%, p = 0.038). CONCLUSION: In Caucasian patients with CHB, with or without cirrhosis, long-term ETV or TDF monotherapy is associated with similar HCC risk, rates of biochemical/virological remission, HBsAg loss and liver transplantation or death, but elastographic reversion of cirrhosis at year 5 was more frequent with TDF. LAY SUMMARY: In a large cohort of Caucasians with chronic hepatitis B treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) monotherapy, cumulative rates of hepatocellular carcinoma did not differ (up to 12 years). Nor did rates of biochemical/virological remission, HBsAg loss and liver transplantation or death. However, elastographic reversion of cirrhosis at year 5 was more frequent in TDF- than ETV-treated patients with pretreatment cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Papatheodoridis GV, Dalekos GN, Idilman R, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol. 2020. PMID: 32553667. doi:10.1016/j.jhep.2020.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。